We report the successful use of r-hirudin (lepirudin) for cardiopulmonary bypass in a 67-year-old man who developed heparin-induced thrombocytopenia type II during heparin treatment of an extensive deep venous thrombosis. Lepirudin was monitored by the modified ecarin clotting time in a "mobile laboratory" set up next to the cardiac theatre, aiming for lepirudin levels of 3.5 to 4.5 µg/ml during bypass. FIGURE 1: Intra-operative results: lepirudin concentration vs time. On-CPB: 11:10, Off-CPB: 12:35, Lepirudin Infusion ceased: 12:26.
Heparin-induced thrombocytopenia and thrombosis (HIT type II) occurs most commonly in patients treated with unfractionated heparin, although crossreaction may occur in association with low-molecular weight heparin and heparinoid therapy. Lepirudin, a recombinant direct thrombin inhibitor, has been approved by the USA Food and Drug Administration, and the Australian Therapeutic Goods Administration for anticoagulation in these patients. However, its use for cardiopulmonary bypass in HIT type II patients is an off-label indication. A team approach involving haematologists, laboratory scientists, anaesthetists, perfusionists and surgeons is vital for the optimum management of these patients. We report our use of lepuridin in the management of a HIT type II patient having coronary artery bypass surgery.
CASE HISTORY
The patient was a previously well 67-year-old man whose past history included a long-standing smoking habit, hypertension and occasional gastrooesophageal reflux. He presented to the Accident and Emergency Department with a two-week history of mild left lower limb pain progressing to a thirty-six hour history of pain and swelling in the same limb. A provisional diagnosis of deep venous thrombosis was made and was subsequently confirmed by ultrasound. The thrombus was non-occlusive and extended from the left femoral to the left common iliac vein. Of note, the ultrasound also demonstrated an infrarenal abdominal aortic aneurysm containing mural thrombus. Apart from a D-dimer level of >9 mg/ml and a serum creatinine of 178 µmol/l, all other blood test results fell within the normal range. In particular, his platelet count was 173x10 9 /l. His admission ECG showed sinus rhythm with evidence of a previous non-Q wave inferior myocardial infarction.
On the day of admission the patient was commenced on subcutaneous enoxaparin (1 mg/kg bd). This was converted to a continuous infusion of unfractionated heparin the next day, commencing at 1000 units/hour. During the first three days of treatment his left leg symptoms persisted. Warfarin therapy was introduced at this time. Concurrently, the patient began to complain of abdominal pain, raising concerns about leaking from his aortic aneurysm. An abdominal CT scan showed an 8.2 cm infrarenal aneurysm extending into the left common iliac artery. Eccentric thrombus was present but there was no evidence of a leak. As his activated partial thromboplastin time (aPTT) was only 50 seconds his heparin infusion was increased to 1600 units/hour. Despite ongoing therapy, the patient continued to complain of left leg and abdominal pain over the next twelve days. At this time a repeat platelet count had fallen to 56x10 9 /l. A provisional diagnosis of HIT type II was made. Heparin therapy was immediately ceased and a danaparoid infusion was commenced. An ELISA test confirmed HIT type II. Three days after ceasing heparin the patient's platelet count had increased to 110x10 9 /l; within a week his platelet count had further increased to 310x10 9 /l.
In view of the size of the patient's aortic aneurysm and the risk of spontaneous rupture an open repair of the aneurysm was planned. A dipyridamole-thallium scan was performed which showed previous inferior wall transmural infarction and mild to moderate reversible inferior and lateral wall ischaemia. A coronary angiogram showed severe disease requiring coronary artery bypass grafting: 70% left main coronary stenosis, 70 to 80% proximal left anterior descending artery stenosis and a totally occluded right coronary artery. A transthoracic echocardiogram showed normal left and right ventricular size and systolic function, mild bi-atrial enlargement and mild mitral and tricuspid regurgitation. Although the wisdom of performing coronary revascularization prior to aortic surgery remains controversial, the evidence of up to moderate inducible ischaemia and a 70% left main coronary stenosis swayed our decision making. Ultimately, we decided to proceed with the cardiac surgery, using lepirudin anticoagulation (see Discussion, below) then await clearance of the platelet antibodies before embarking upon the aortic surgery.
The Surgical Preparation
On the morning of surgery the patient was premedicated with morphine 10 mg IM and temazepam 20 mg orally and his usual antihypertensive medication was given. Intravenous access was established, a left femoral arterial line was sited and a multi-access catheter was inserted into the right internal jugular vein through which was passed a triple-lumen central line. All catheters and flush fluids were devoid of heparin. The cardiopulmonary bypass circuit was primed with 0.2 mg/kg (14.4 mg) of lepirudin.
After preoxygenation, anaesthesia was induced using a combination of midazolam, fentanyl and propofol. Pancuronium was used to facilitate endotracheal intubation. Anaesthesia was maintained with a propofol infusion and isoflurane in a mixture of oxygen and air. Intermittent glyceryl trinitrate, esmolol and atenolol were used to maintain haemodynamic stability. It is not routine practice in our institution to use prophylactic antifibrinolytics for primary coronary artery bypass graft procedures and we chose not to change this practice for this patient. Transoesophageal echocardiography was performed. The findings were not significantly different from the preoperative transthoracic study.
Prior to cardiac cannulation a bolus dose of lepirudin (0.25 mg/kg; 18 mg) was administered. This was followed by a continuous infusion of 0.5mg/ minute, which targeted a lepirudin concentration of 3.5 to 4.5 µg/ml. After ensuring adequate anticoagulation, based on a modified escarin clotting time result, cardiopulmonary bypass was commenced and temperature was allowed to drift.
Monitoring in Theatre
The intraoperative lepirudin infusion rate was adjusted according to the algorithm described by Poetzsch and Madlener 1 . As this was a pilot case, we performed modified ecarin clotting times by both the ACT II device (Medtronic, Inc, Minneapolis, MN, U.S.A.) and tilt-tube methods. Lepirudin levels were measured every 15 to 20 minutes throughout the procedure. The time taken for clot formation was plotted on the patient's preoperatively-derived standard escarin clotting time curve and the resultant lepirudin level was determined. Infusion rate adjustments were made to maintain lepirudin levels between 3.5 and 4.5 µg/ml (see Figure 2 ). This monitoring continued into the postoperative phase until the lepirudin levels had fallen to 1.4 µg/ml. Three vessels were bypassed uneventfully (left internal mammary to left anterior descending artery, right internal mammary to left circumflex artery and left radial to posterior descending artery). The patient was rewarmed and 10 minutes prior to the anticipated separation from bypass, lepirudin in-fusion was ceased. Weaning from bypass proceeded smoothly. In view of concerns regarding the clearance of lepirudin in this patient with impaired renal function, five units of fresh frozen plasma were transfused prophylactically in the operating room. In addition, one unit of packed cells was transfused. In retrospect, the use of plasma may not have been not required. The time taken to secure haemostasis was no different from that for our routine coronary artery bypass graft patients given heparin with protamine neutralization. At the conclusion of surgery the patient was transferred to the Intensive Care Unit. He was successfully extubated within three hours of his arrival in the unit. Haemodynamics and urine output remained stable during this time. Day one mediastinal drainage was 390 ml and total drainage was 640 ml. Despite the patient's impaired renal function, the lepirudin levels two and a half hours after surgery had fallen to 1.4 µg/ml. The remaining postoperative course was uncomplicated.
DISCUSSION
Heparin is the most commonly used parenteral anticoagulant for both prophylactic and therapeutic use. It has been associated with two types of thrombocytopaenia, namely, heparin-induced thrombocytopaenia types I and II. The former refers to a nonimmune, mild, early-onset thrombocytopenia; the latter is a severe, immune-mediated, delayed-onset thrombocytopenia often complicated by thrombotic events.
In 1 to 5% of heparin-treated patients, HIT type II may develop 2 : most commonly, a mild to moderate thrombocytopenia develops 5 to 10 days after commencement of heparin therapy. In over 50% of these patients potentially life-threatening thrombotic complications then ensue. Although HIT type II most commonly results from therapeutic heparin administration, it has been associated with heparincontaining flushes 3, 4 and heparin-coated pulmonary artery catheters 5 . Thus, we avoided the use of a pulmonary artery catheter and all flush fluid was devoid of heparin.
HIT type II results from the formation of heparindependent antibodies 6 . These antibodies only develop in patients exposed to exogenous heparin and not the endogenous form, heparan sulphate 7 . In HIT type II, the antibody reaction is directed at platelet factor 4 (PF4) and heparin complex. Heparin binds to PF4 to form heparin-PF4 complexes. These complexes then stimulate the production of antibody to the PF4 in the complex, in a reaction akin to an autoimmune response. The heparin-PF4-antibody complexes stimulate platelet activation and thrombin generation. Further PF4 is released from the activated platelets, so accelerating the process 8 . Despite the thrombocytopenia, HIT is a hypercoagulable condition due to the resultant very high levels of thrombin and thrombin-antithrombin complexes, together with the loss of the anticoagulant action of heparin as it binds to PF4. HIT type II does not involve an anamnestic immune response. That is, rapid-onset HIT only occurs when heparin is administered to patients with circulating antibody. Had it been possible to defer cardiac surgery until our patient had become antibody negative, heparin could have been used as the anticoagulant for bypass. Clearly, such a delay was not possible. Our patient was still in the very early phases of recovery from HIT type II and was still antibody positive, so an alternative anticoagulant for bypass was required. Ideally, the chosen agent would have a rapid onset of action, be easily and accurately monitored in the operating room, have a rapid offset independent of major organ function, have an easily administered antidote and have a satisfactory safety profile. Various agents have been used for bypass in patients with HIT type II (e.g. desirudin, bivalirudin, iloprost, danaparoid, argatroban etc), but most alternatives have resulted in excessive bleeding. Danaparoid, a polysulphated glycosaminoglycan composed of heparan sulphate 84%, dermatan sulphate 12%, and chondroitin sulphate 4% was initially commenced as a bridging anticoagulant before surgery. Danaparoid was not chosen as the anticoagulant for surgery because of a lack of a specific antidote and its prolonged anti-Xa activity (approximately 25 hours). These features may contribute to excessive postoperative bleeding 9 .
Lepirudin was chosen because of its reported successful use in cardiac surgery, a well-established protocol 10 for its use in cardiac surgery, the ability to monitor its action at the bedside, and its availability for use in Australia for this indication (albeit offlabel). Its use requires the establishment of a patientspecific nomogram and to achieve this the patient was admitted three days prior to his planned coronary surgery. Warfarin was ceased three days preoperatively and danaparoid one day prior to surgery. An inferior vena caval filter was sited prophylactically.
It has been established that the ideal concentrations of lepirudin for cardiopulmonary bypass are 3.5 to 4.5 µg/ml 11 . Standard laboratory measures such as the aPTT are unreliable at levels above 2.0 µg/ml but Poetzsch et al 12, 13 have demonstrated that the ecarin clotting time is the test of choice for monitoring such high levels of lepirudin. Unfortunately, this test is dependent upon sufficient levels of prothrombin and fibrinogen, both of which are diluted during cardiopulmonary bypass. To overcome this limitation Koster et al 14 developed the modified ecarin clotting time, which corrects for the haemodilution of the aforementioned procoagulants. The modified ecarin clotting time uses the ACT II clotting device. Lyophilized Ecarin (Sigma Cat. No. E-0504) is dissolved in HEPES buffer (pH 7.0) to a stock solution concentration of 20 U/ml. Further dilutions can be made to concentations of 5 U/ml and 2 U/ml, as required. Blank ACT II cartridges containing 75 µl of standard normal plasma (Dade Behring, Marburg, Germany) are prewarmed on the instrument before the addition of 75 µl of the patient's whole blood and 75 µl of the ecarin reagent. The time to clot formation is determined and recorded. Each test is performed in duplicate and can also be repeated manually, for confirmation of accuracy, using the tilttube method in a 37°C waterbath. Our inexperience with this drug and its monitoring encouraged us to use both techniques on this occasion. The presence of standard normal plasma in the ACT II cartridges overcomes the cardiopulmonary bypass-induced dilution of the essential procoagulants, prothrombin and fibrinogen.
The ecarin clotting time assay is based on the principle of ecarin-induced conversion of prothrombin to meizothrombin. Meizothrombin inhibits lepirudin by the formation of stable 1:1 complexes. Following neutralization of lepirudin, coagulation is initiated by the residual meizothrombin via the conversion of fibrinogen to fibrin. In this way the time to clot formation is directly related to the level of lepirudin present 14 .
The ideal ecarin concentration is that which produces a standard calibration curve with steep linearity. Such a curve will maximize the separation time between the concentrations of lepirudin and ensure maximum sensitivity. Each patient has a unique coagulation status and, hence, a unique response to lepirudin. It is ideal to establish standard ecarin clotting time calibration curves for each patient prior to its use to enable precise measurements of lepirudin levels. For this reason, prior to surgery in our case, a sample of citrated whole blood was collected. This sample was spiked with known amounts of lepirudin (Refludan: Pharmion) to create a series of samples containing increasing concentrations of lepirudin from 0 to 5 µg/ml. Modified ecarin clotting times, as described, were performed on these samples by three methods-the ACT II device at a concentration of 5 U/ml escarin (as established by Koster et al 14 ) and by the manual tilt-tube water-bath technique at concentrations of 2 U/ml and 5 U/ml ecarin (to establish clear discrimination of lepirudin levels). Standard calibration curves for each method were constructed and target times corresponding to the required lepirudin levels were established (Figure 1 ).
Lepirudin is a recombinant direct thrombin inhibitor derived from the saliva of the medicinal leech, Hirudo medicinalis. It has been approved for use as an anticoagulant in the treatment of patients with HIT II. There is no specific neutralizing antidote. The usual t 1/2 of lepirudin (70-90 minutes) is prolonged in renal failure and this was a concern because our patient had impaired renal function. Bivalirudin, with its lack of dependence on organsystem function for elimination, would have been an ideal alternative but was not available for use in Australia.
To the best of our knowledge this is the first time lepirudin has been used during cardiopulmonary bypass in Australia. The success of this case was in large part due to intensive preoperative preparation. The establishment of a patient-specific modified ecarin clotting time calibration curve enabled accurate adjustments of the lepirudin infusion. The maintenance of lepirudin levels of 3.5 to 4.5 µg/ml ensured absence of clotting in the bypass circuit and reasonable confidence that excessive bleeding would not develop. The apparatus required to perform modified ecarin clotting time measures was not cumbersome and a "mini laboratory" was easily set up in a room adjacent to the operating room. This allowed direct communication between anaesthetists, haematologists, scientists, perfusionists and surgeons. From the laboratory point of view this testing protocol was labour intensive and required experience and expertise in its establishment. Having developed the protocol it has been shown to be relatively easy to use and can now be applied within a short time frame, even in an emergency situation.
Our experience would encourage us to use lepirudin in the future for heparin-induced thrombocytopenic patients requiring cardiopulmonary bypass. These cases are difficult to manage and it is our belief that a multidisciplinary approach involving close communication between the haematologists, laboratory scientists, anaesthetists, perfusionists and surgeons was a key to our success.
